Biomedical subjects

D V Riabenko

Publications and source records attributed to D V Riabenko.

6 recordsLinked to original sources

PubMed1995

[Cardiodynamics and left ventricular myocardial contractile reserve in patients with dilated cardiomyopathy].

Cardiodynamics and contractile myocardial reserves were measured at radionuclide ventriculography and volume loading of the heart (upward position of the legs at 45 degrees) in 43 patients with dilated cardiomyopathy (DCM). The patients displayed a sharp fall in total and regional ejection fractions (BP), stroke volume (SV), cardiac index, a decrease in Vcf and maximum ejection rate (Vmax) in combination with notable cardiomegaly. There were two types of responses to loading test: positive (increased BP, SV, Vcf, Vmax, reduced end-systolic volume) and negative (decreased EP, SV, Vcf, Vmax, increased end-systolic volume) Inotropic effects evidencing the existence or depletion of myocardial contractile reserve. Loading test in DCM patients allows more objective evaluation of the patient's condition and validated therapeutic measures.

Adult↗

PubMed1993

[Left ventricular function in patients with dilated cardiomyopathy].

Functional state of left ventricle was studied in 43 patients with dilated cardiomyopathy. All the patients showed pronouncedly reduced total ejection, stroke volume and cardiac index, increased final diastolic and final systolic volumes, decreased ejection rate indices. Analysis of regional contractility of left ventricle allowed to detect significant fall of ejection fraction in 96.3% of segments. Diastolic dysfunction was characterized by disorders of isovolumetric relaxation, changes in hemodynamical structure and contribution of atrial systole to ventricular filling, decrease of volumetric compliance of left ventricle. The data obtained give a reason to consider that appropriate therapy of dilated cardiomyopathy should be carried out with taking into account both systolic and diastolic left ventricle dysfunction.

Adult↗

PubMedDate not supplied

[The clinico-hemodynamic effects of losartan in treating patients with chronic heart failure].

Clinical and hemodynamic effects were studied of the blockader of AII receptors lozartan in patients with chronic cardiac insufficiency (ChCI). Inclusion of losartan into the conventional therapy of ChCI is accompanied by a lowering of the functional class in patients and improvement of haemodynamic maintenance of the physical exercise performance as evidenced by veloergometry. An 8-week's course of lozartan therapy leads also to a decrease in the anterior-posterior dimensions of the left auricle and an increase in the left ventricular ejection fraction in ChCI patients.

Adult↗

PubMedDate not supplied

[ATP activity of myocardial actomyosin complex in patients with dilated cardiomyopathy].

ATP activity of actomyosin in dilated cardiomyopathy (DCMP) was studied together with impact on the above activity of tropomyosin-troponin regulatory complexes recovered from the normal myocardium and cardiac muscle of a DCMP patient. Recordable in DCMP was a striking decline (1.5-fold) in ATP activity of actomyosin. But no significant difference was to be seen in sensitivity to Ca2+ ions of actomyosins obtained from the normal myocardium and cardiac muscle of the DCMP patient. The cardial tropomyosin-troponin regulatory complex from the DCMP patient's myocardium was shown to be endowed with somewhat more manifest activity compared to the analogous complex recovered from the normal myocardium.

Actomyosin↗

PubMedDate not supplied

[Survival and risk factors in patients with chronic cardiac insufficiency (results of a long-term prospective observation)].

Based on a 10-year prospective follow-up a study was made into survival in 68 patients with chronic cardiac insufficiency (CCI) having developed as a result of hypertensive disease and postinfarction cardiosclerosis. Also studied in the above series were risk factors for death. It has been found out that life span in CCI is, in the mean, seven years while risk for death beyond 10 years increases six-fold. The identified prognostic factors included etiology of CCI, age of patients, end-systolic volume of the left ventricle, and a week dosage of furosemide. It was etiology of CCI that proved to be the most significant risk factor. In some patients with postinfarction cardiosclerosis and CCI average life span comes up to more than five years, with risk for death being significantly higher than in CCI patients with CCI having developed in the wake of hypertensive disease over the whole of the period of study.

Adult↗

PubMedDate not supplied

[Use of inhibitors of the angiotensin-converting enzyme and the beta-adrenoblocker metoprolol combined in treatment of chronic cardiac insufficiency].

Clinical-and-hemodynamic effects were studied of a supplementary use of a selective beta-adrenoblocker metoprolol in an ongoing therapy of chronic cardiac insufficiency (CCI) with inhibitors of the angiotensin-converting enzyme (ACEI) and diuretics. It has been found out that long (over 8 weeks) course of therapy supplemented with metoprolol results in improvement of the left ventricular systolic function and lowering of the functional class. Long-term administration of metoprolol enhances tolerance to a graded physical exercise in CCI patients, which observation is accompanied by a more economic character of its performance. The findings secured validate the expediency of a supplementary use of the beta-adrenoblocker metoprolol in the routine regimen of the supporting treatment of CCI patients involving the use of ACEI plus a diuretic.

Adrenergic beta-Antagonists↗